ArticleJournal of kidney cancer and VHL2026
Gastric Neuroendocrine Tumor Presenting Atypically in von Hippel-Lindau Disease: A Case Report.
Article in Journal of kidney cancer and VHL, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
von Hippel-Lindau (VHL) disease, an autosomal dominant inherited disorder resulting from mutations in the VHL gene, is known to be associated with the development of neuroendocrine tumors (NET) in various organs, including the adrenal gland, pancreas, and paraganglion. However, the development of gastric NET (gNET) in VHL disease has not been reported. Limited studies have suggested that clear cell change is a distinctive feature of VHL-associated tumors. Herein, we first report a case of a patient with VHL syndrome who presented with a gNET showing clear cell change, an unusual morphological characteristic of gNET, and harbored a pathogenic germline VHL mutation (c.351 G>T). The patient underwent surgical treatment for retinal hemangioblastoma, gNET, and renal cell carcinoma, in addition to receiving endocrine therapy and antiangiogenic drugs. The patient survived for 17 years. Our case highlights the possibility of VHL-associated NET development in uncommon locations. Further studies are required to elucidate the correlation between VHL mutation sites and the clinical manifestation of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.